Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af effektiviteten af ​​neothelium ft i behandlingen af ​​kroniske åbne sår

9. november 2026 opdateret af: NuScience Medical Biologics, LLC

Evaluering af effektiviteten af ​​neothelium ft i helingen af ​​kroniske åbne sår: et randomiseret kontrolleret multicenterforsøg

This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.

The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

132

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Angelina Ferguson, DNP
  • Telefonnummer: (985) 629-4013
  • E-mail: info@sygnola.com

Undersøgelse Kontakt Backup

Studiesteder

    • Louisiana
      • Denham Springs, Louisiana, Forenede Stater, 70726
        • Rekruttering
        • MedCentris of Denham Springs
        • Ledende efterforsker:
          • Monique Consoer, NP
        • Kontakt:
      • Hammond, Louisiana, Forenede Stater, 70403
      • Lafayette, Louisiana, Forenede Stater, 70507
        • Afsluttet
        • MedCentris of Carencro
      • Leesville, Louisiana, Forenede Stater, 71146
        • Rekruttering
        • MedCentris of Leesville
        • Ledende efterforsker:
          • Stefanie Corley, FNP
        • Kontakt:
      • Many, Louisiana, Forenede Stater, 71449
      • Marksville, Louisiana, Forenede Stater, 71351
      • Metairie, Louisiana, Forenede Stater, 70001
        • Rekruttering
        • MedCentris of Metairie
        • Kontakt:
        • Ledende efterforsker:
          • Sarah Logrande, NP
      • Minden, Louisiana, Forenede Stater, 71055
      • Monroe, Louisiana, Forenede Stater, 71201
        • Ikke rekrutterer endnu
        • MedCentris of Monroe
        • Ledende efterforsker:
          • Libbi Trawick, NP
        • Kontakt:
      • Slidell, Louisiana, Forenede Stater, 70458
        • Rekruttering
        • MedCentris of Slidell
        • Ledende efterforsker:
          • Katie Schloegel, FNP
        • Kontakt:
    • Mississippi
      • D'Iberville, Mississippi, Forenede Stater, 39540
        • Afsluttet
        • MedCentris of D'iberville
      • McComb, Mississippi, Forenede Stater, 39648
        • Afsluttet
        • MedCentris of McComb
      • Natchez, Mississippi, Forenede Stater, 39120
        • Afsluttet
        • MedCentris of Natchez
      • Southaven, Mississippi, Forenede Stater, 38671
        • Rekruttering
        • MedCentris of Southaven
        • Ledende efterforsker:
          • Carlene McAllister, NP
        • Kontakt:
    • New York
      • Brooklyn, New York, Forenede Stater, 11234
        • Rekruttering
        • Northeast Podiatry Consultant
        • Kontakt:
        • Ledende efterforsker:
          • David Simon, DPM, FACFAS

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or Female, 18 years of age or older
  2. Subject has a medical diagnosis of "other" Open wound
  3. Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
  4. Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
  5. Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
  6. Subject has an Open wound without infection or clinically visible exposed bone
  7. Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
  8. Index ulcer has a maximum depth of 1cm at screening visit 1
  9. The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
  10. Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
  11. Index ulcer is free of infection prior to randomization and during screening phase.
  12. Index ulcer is free of necrotic debris prior to NeoThelium FT application
  13. Female subjects of childbearing potential having a negative pregnancy test prior to randomization
  14. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
  15. Subject is able and willing to follow the protocol requirements
  16. Subject had signed informed consent
  17. If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm

Exclusion Criteria:

  1. Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
  2. Subject has a known life expectancy of <1 year
  3. Subject is unable to comply with protocol treatment
  4. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
  5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
  6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
  7. Known contraindications to tissue-engineered allograft
  8. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
  9. Subject is pregnant or breastfeeding
  10. Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
  11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
  12. Open wound with active infection
  13. Wound depth with visible exposed bone
  14. HBOT within 14 days prior to randomization
  15. Revascularization surgery on the index wound leg within 30 days of screening phase
  16. Index wound suspicious of neoplasm in the opinion of the principal investigator

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: No Intervention: Standard of Care

Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading

Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading

Eksperimentel: Intervention: NeoThelium FT & Standard of Care

Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading

NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Complete Wound Closure
Tidsramme: 1-12 weeks

The primary endpoint will be the percentage of target ulcers that achieve complete wound closure.

1-12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage Wound Area Change
Tidsramme: 1-12 weeks

The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination.

1-12 weeks
Pain Assessment
Tidsramme: Day 0, Day 14, Day 35, Day 56, Day 84

Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points

Day 0, Day 14, Day 35, Day 56, Day 84

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Follow-Up Closure
Tidsramme: 2 weeks

Number of wounds remaining closed during the 2-week follow-up

2 weeks
Adverse Events and Serious Adverse Events
Tidsramme: Day -14 through 91 days

The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported.

Day -14 through 91 days
Time to Closure
Tidsramme: 1-12 weeks

Average number of grafts and/or weeks used to achieve wound closure

1-12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Angelina Ferguson, DNP, SygNola, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. oktober 2025

Primær færdiggørelse (Anslået)

31. december 2027

Studieafslutning (Anslået)

30. januar 2028

Datoer for studieregistrering

Først indsendt

31. marts 2025

Først indsendt, der opfyldte QC-kriterier

8. april 2025

Først opslået (Faktiske)

9. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner